Continuous Improvement Versus Innovation: The Case for Sipuleucel-T

被引：3
|
作者：
Tombal, Bertrand [1 ]
机构：
[1] Catholic Univ Louvain, Serv Urol, Clin Univ St Luc, B-1200 Brussels, Belgium
来源：
EUROPEAN UROLOGY | 2012年 / 61卷 / 04期
关键词：
PROSTATE-CANCER; MITOXANTRONE; PREDNISONE; DOCETAXEL;
D O I：
10.1016/j.eururo.2011.11.033
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：648 / 649
页数：2
相关论文
共 50 条
  • [31] Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
    Huber, Marie L.
    Haynes, Laura
    Parker, Chris
    Iversen, Peter
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (04) : 273 - 279
  • [32] Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
    Kantoff, Philip W.
    Higano, Celestia S.
    Shore, Neal D.
    Berger, E. Roy
    Small, Eric J.
    Penson, David F.
    Redfern, Charles H.
    Ferrari, Anna C.
    Dreicer, Robert
    Sims, Robert B.
    Xu, Yi
    Frohlich, Mark W.
    Schellhammer, Paul F.
    Ahmed, T.
    Amin, A.
    Arseneau, J.
    Barth, N.
    Bernstein, G.
    Bracken, B.
    Burch, P.
    Caggiano, V.
    Chin, J.
    Chodak, G.
    Chu, F.
    Corman, J.
    Curti, B.
    Dawson, N.
    Deeken, J. F.
    Dubernet, T.
    Fishman, M.
    Flanigan, R.
    Gailani, F.
    Garbo, L.
    Gardner, T.
    Gelmann, E.
    George, D.
    Godfrey, T.
    Gomella, L.
    Guerra, M.
    Hall, S.
    Hanson, J.
    Israeli, R.
    Jancis, E.
    Jewett, M. A. S.
    Kassabian, V.
    Katz, J.
    Klotz, L.
    Koeneman, K.
    Koh, H.
    Kratzke, R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (05) : 411 - 422
  • [33] Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm
    Gulley, James L.
    Mulders, Peter
    Albers, Peter
    Banchereau, Jacques
    Bolla, Michel
    Pantel, Klaus
    Powles, Thomas
    ONCOIMMUNOLOGY, 2016, 5 (04):
  • [34] Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions
    Handy, Catherine E.
    Antonarakis, Emmanuel S.
    FUTURE ONCOLOGY, 2018, 14 (10) : 907 - 917
  • [35] Sipuleucel-T in Metastatic Castration-Resistant Prostate CancerProfile Report
    Greg L. Plosker
    BioDrugs, 2011, 25 : 255 - 256
  • [36] Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer
    Hannan, Raquibul
    Dohopolski, Michael J.
    Pop, Laurentiu M.
    Mannala, Samantha
    Watumull, Lori
    Mathews, Dana
    Gao, Ang
    Garant, Aurelie
    Arriaga, Yull E.
    Bowman, Isaac
    Chung, Jin-Sung
    Wang, Jing
    Ariizumi, Kiyoshi
    Ahn, Chul
    Timmerman, Robert
    Courtney, Kevin
    BIOMEDICINES, 2022, 10 (06)
  • [37] What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence
    Hu, Rachel
    George, Daniel J.
    Zhang, Tian
    THERAPEUTIC ADVANCES IN UROLOGY, 2016, 8 (04) : 272 - 278
  • [38] Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine
    Wargowski, Ellen
    Johnson, Laura E.
    Eickhoff, Jens C.
    Delmastro, Lauren
    Staab, Mary Jane
    Liu, Glenn
    McNeel, Douglas G.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [39] Strategies for Optimizing the Clinical Impact of Immunotherapeutic Agents Such as Sipuleucel-T in Prostate Cancer
    Madan, Ravi A.
    Schwaab, Thomas
    Gulley, James L.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (12): : 1505 - 1512
  • [40] Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
    Peter F. Mulders
    Maria De Santis
    Thomas Powles
    Karim Fizazi
    Cancer Immunology, Immunotherapy, 2015, 64 : 655 - 663
12345